Cabozantinib can produce durable responses in patients with advanced MiT family translocation renal cell carcinoma (TRCC), according to research published in The Oncologist.
Researchers found evidence to suggest that cabozantinib may produce more durable responses than other VEGFR tyrosine kinase inhibitors (TKIs) or immune checkpoint inhibitors.
The researchers evaluated cabozantinib in 52 patients with metastatic TRCC. The majority of the cohort had poor- or intermediate-risk disease.
Continue Reading
Patients received cabozantinib as frontline therapy (21.2%), second-line therapy (28.8%), or third-line therapy or beyond (50%).
Nine patients (17.3%) had an objective response to cabozantinib, which included 2 complete responses and 7 partial responses. Half of patients (26/52) had stable disease as their best response.
With a median follow-up of 25.1 months, the median progression-free survival (PFS) was 6.8 months, and the median overall survival was 18.3 months.
The researchers noted that this PFS was longer than some historically reported PFS results with VEGFR-TKIs in patients with pretreated TRCC, which ranged from 3 months to 8.2 months.
The team also noted that 32.7% of patients in the current study had progression as their best response, compared with 62.5% of patients treated with first-line VEGFR-TKI in a prior study.
There were no unexpected toxicities or treatment-related deaths in the current study.
“This multicenter, retrospective study, in the absence of available prospective data, provides evidence supporting the activity of cabozantinib in the control of advanced MiT family RCC,” the researchers wrote. “Given the rarity of this histological subtype of RCC, international collaboration and prospective studies are necessary to identify efficacious therapies for this rare disease that lacks prospectively validated treatment options.”
Disclosure: Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.
Reference
Thouvenin J, Alhalabi O, Carlo M, et al. Efficacy of cabozantinib in metastatic MiT family translocation renal cell carcinomas. Oncologist. Published online August 18, 2022. doi:10.1093/oncolo/oyac158
